Dossier
emideltide
Coverage of emideltide in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
An FDA advisory panel recommended allowing compounding pharmacies to manufacture peptides epitalon and semax but voted against emideltide. Amgen is challenging the FDA's proposal to withdraw its drug Tavneos from the U.S. market, citing new evidence from over 70 real-world studies.
- FDA advisory panel narrowly rejects compounding of one peptide, back another
An FDA advisory panel recommended allowing compounding pharmacies to manufacture the peptide epitalon but narrowly voted against emideltide. The decision brings health secretary Robert F. Kennedy, Jr. closer to expanding access to unapproved peptides, which have gained popularity through social media influencers.